BYD
6.12.2023 13:07:31 CET | Business Wire | Press release
BYD Ecuador (hereafter referred to as BYD) and the Latin American Energy Organization (OLADE) announced that an Interinstitutional Cooperation Agreement was formalized recently, with the aim of advancing the cause of electric mobility in Latin America and the Caribbean.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206085642/en/
BYD and OLADE Form Strategic Partnership (Left: Executive Secretary of OLADE, Andrés Rebolledo Smitmans; Right: Country Manager of BYD Ecuador, Jorge Burbano) (Photo: Business Wire)
OLADE, under the leadership of its Executive Secretary, Andrés Rebolledo Smitmans, and BYD, represented by Jorge Burbano, Country Manager of BYD Ecuador, have signed this agreement, solidifying their joint commitment to promoting electric vehicles and accelerating energy transitions in the region.
Established in 1973, OLADE is a respected intergovernmental cooperation organization dedicated to fostering energy integration, development, and conservation in Latin America and the Caribbean. In contrast, BYD, founded in 1995, stands as a leading technology company with a focus on innovation in diverse industries, including automobiles, electronics, rail transit, and new energy.
The collaboration outlined in this agreement will encompass crucial elements such as promoting sustainable mobility, conducting workshops, and providing specialized training in electromobility. These initiatives will target both the public and private sectors, academia, specialized guilds, and civil society in Latin America and the Caribbean. Moreover, the partnership will involve site visits and technical demonstrations at OLADE facilities, specifically focusing on electromobility, for universities, technology centers, educational institutions, guilds, and related organizations. Additionally, BYD’s vehicles will be utilized in OLADE’s electromobility studies, aligning with OLADE’s work plans.
BYD will significantly contribute to this collaboration by providing a TANG EV electric vehicle model along with a charging station. This equipment will be used to demonstrate the electric infrastructure and the vehicle's autonomy, emphasizing the advantages of electric vehicles.
Commenting on the partnership, Jorge Burbano, Country Manager of BYD Ecuador, stated, “We are deeply honored to collaborate with OLADE, leveraging our expertise in electric mobility and energy solutions. Our joint mission is crucial – reducing CO2 emissions and contributing to global efforts to cool the earth by 1℃. I am confident that our cooperation will serve as a beacon for knowledge transfer and research, fostering sustainable development and energy security in the region.”
The Executive Secretary of OLADE, Andrés Rebolledo, highlighted the significance of the recent agreement as a key commitment to regional energy integration and cooperation for the benefit of OLADE’s 27 member countries. He emphasized the importance of transitioning to a sustainable vision in Latin America and the Caribbean, advocating for a long-term perspective in energy integration. This milestone signifies a notable collaboration between both entities, dedicated to a cleaner and more sustainable future for the region. It focuses on priority areas such as electrification of mobility and sustainable mobility training, with the possibility of agreeing on specific agreements for the execution of projects aligned with their shared objectives.
Through this agreement, BYD and OLADE reaffirm their dedication to regional energy integration and cooperation for the benefit of member countries. By closely collaborating and implementing joint projects, they aim to promote sustainable development and optimize energy resources and transportation through clean energy sources in the region.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, DM-i Super Hybrid Technology, e Platform 3.0, CTB Technology, e4 Platform, BYD DiSus Intelligent Body Control System, and DMO super hybrid system. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 10 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206085642/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom